[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345419-105":59,"doc-detail-345419-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-ovarian-cancer-associated-antigens-forming-complexes-with-autoantibodies","Identification of ovarian cancer-associated antigens forming complexes with autoantibodies","","Tumor-associated antigen (Ag)-autoantibody (AAb) complexes are detected in circulation across multiple cancer types, yet their clinical relevance is not well understood. To address this, immunoblotting was performed on human ovarian cancer cell lines (AMOC2, OVCAR3, SKOV3) using free antibodies or antigen-dissociated antibodies derived from ovarian cancer ascites and healthy sera. Ag-AAb complexes from ascites were also analyzed by mass spectrometry. Enzyme-linked immunosorbent assay evaluated SPON1 in free versus complexed forms, and the study identified dominant complex formation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-ovarian-cancer-associated-antigens-forming-complexes-with-autoantibodies/345419/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-ovarian-cancer-associated-antigens-forming-complexes-with-autoantibodies/345419.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of this study on ovarian cancer-associated antigens?","Question",{"text":112,"@type":113},"To determine how tumor-associated antigen and autoantibodies exist together in ovarian cancer patients, and to identify antigens that form complexes with autoantibodies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were antigen-autoantibody complexes and antigens identified in ovarian cancer ascites?",{"text":117,"@type":113},"The study used immunoblotting to compare free antibodies versus antigen-dissociated antibodies, mass spectrometry to profile antigens within isolated Ag-AAb complexes, and ELISA to assess an extracellular matrix candidate antigen (SPON1) in free versus complexed forms.",{"name":119,"@type":110,"acceptedAnswer":120},"What key finding emerged regarding autoantibody forms in ovarian cancer ascites?",{"text":121,"@type":113},"Tumor-associated autoantibodies in ovarian cancer ascites predominantly existed in antigen-autoantibody complexes rather than as free autoantibodies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345419,1790902510,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Fujimori et al. Journal of Ovarian Research (2026) 19:187 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02089-8](https://doi.org/10.1186/s13048-026-02089-8)  \nRESEARCH Open Access  \nIdentification of ovarian cancerassociated antigens forming complexes with autoantibodies  \nMimori Fujimori 1†, Kai Uryu2†, Makoto Kobayashi2*†, Kotaro Sugimoto2, Yuta Endo 1,3, Shigenori Furukawa 1,3, Shu Soeda1,3, Yoshio Kodera4, Keiya Fujimori 1,3,5 and Hideki Chiba2*  \nAbstract  \nBackground Tumor-associated antigen (Ag)-autoantibody (AAb) complexes are known to be present in the circulation of patients with multiple types of cancer; however, their significance remains poorly understood. Methods We performed immunoblotting of whole cell extracts ofthe human ovarian cancer cell lines AMOC2, OVCAR3 and SKOV3 with either free antibodies (Abs) or antigen-dissociated Abs obtained from ovarian cancer ascites and healthy sera. In addition, Ag-AAb complexes isolated from ovarian cancer ascites were analyzed by mass spectrometry to identify tumor-associated antigens. Enzyme-linked immunosorbent assay (ELISA) was then used to evaluate the presence of one extracellular matrix (ECM) candidate antigen, SPON1, in its free versus complexed form in ascites and sera.  \nResults Immunoblotting revealed that tumor-associated AAbs in ovarian cancer ascites predominantly exist in Ag-AAb complexes rather than as free AAbs. Proteomic profiling identified 72 tumor-associated antigens enriched in ovarian cancer ascites compared with healthy and disease control sera; more than half were ECM-or epithelial– mesenchymal transition (EMT)-related proteins. ELISA demonstrated that SPON1 was preferentially detected as Ag-AAb complexes, but not in its free form, in both ascites and sera of ovarian cancer patients.  \nConclusion We uncovered that AAbs predominantly form complexes with tumor-associated antigens in ovarian cancer patients. Since the presence of Ag-AAb complexes has been overlooked in many reports, the identification of tumor-associated antigens and AAbs from Ag-AAb complexes would provide novel insights into their relevance to a variety of cancers and other diseases.  \nKeywords Autoantibody, Tumor-associated antigen, Antigen-autoantibody complex, Cancer, Epithelial ovarian cancer, SPON1  \n†Mimori Fujimori, Kai Uryu and Makoto Kobayashi share the first authorship.  \n*Correspondence: Makoto Kobayashi [makokoba@fmu.ac.jp](makokoba@fmu.ac.jp)[ ](makokoba@fmu.ac.jp)Hideki Chiba [hidchiba@fmu.ac.jp](hidchiba@fmu.ac.jp)  \n1Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan  \n2Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan  \n3Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan  \n4Center for Disease Proteomics, School of Science, Kitasato University, Sagamihara, Kanagawa, Japan  \n5Department of Regional Medical Support for Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will n","cbCairabIUmTmfJR","https://ap.wps.com/l/cbCairabIUmTmfJR","pdf",3711573,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Global burden and subtype overview\n## Limitations of existing biomarkers (CA-125, HE4)\n## Screening evidence and unmet need","[{\"question\":\"What was the main objective of this study on ovarian cancer-associated antigens?\",\"answer\":\"To determine how tumor-associated antigen and autoantibodies exist together in ovarian cancer patients, and to identify antigens that form complexes with autoantibodies.\"},{\"question\":\"How were antigen-autoantibody complexes and antigens identified in ovarian cancer ascites?\",\"answer\":\"The study used immunoblotting to compare free antibodies versus antigen-dissociated antibodies, mass spectrometry to profile antigens within isolated Ag-AAb complexes, and ELISA to assess an extracellular matrix candidate antigen (SPON1) in free versus complexed forms.\"},{\"question\":\"What key finding emerged regarding autoantibody forms in ovarian cancer ascites?\",\"answer\":\"Tumor-associated autoantibodies in ovarian cancer ascites predominantly existed in antigen-autoantibody complexes rather than as free autoantibodies.\"}]","Identification of ovarian cancer-associated antigens forming complexes with autoantibodies | PDF",1790057608,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff9266fb9ec9cd9f9daaa2519e811e1a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/891b76e60641d742b2732665c2a65bfe.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38e3704ee710c923a301cc1ac708e48d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59336d438de9074ca857560d9845f9d8.webp",980,1306]